Scientists in California have ‘unboiled’ an egg – with some interesting implications for biopharma...

Can pharma get over its IP anxiety and embrace meaningful partnerships?

Primers on the science of metabolic engineering.

Why we need research in space? We spoke with Cynthia Bouthot at the Center for the Advancement of Science in Space (CASIS) to find out.

In today’s aggressive, cost-cutting climate, the desire to switch from batch to continuous manufacturing is strong.

Aptar Pharma announces the re-launch of its Bag-on-Valve (BOV) activities in its Radolfzell manufacturing site

How can we overcome bioavailability challenges in our increasingly complex drug pipeline?

Having witnessed the evolution of operational excellence (OPEX), how do you implement it – and how do you ensure continued success?

A new model for cocrystal formation could be a powerful tool for formulation scientists – no crystal structures required, it’s all about the surface contacts.

If pharma is to retain its reputation as an innovator, companies must be brave enough to explore new areas, new targets and new technologies.